dr. song on zanubrutinib activity in relapsed/refractory mcl
Published 5 years ago • 148 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:20
dr. goy the evolution of treatment in relapsed/refractory mcl
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
2:23
yuqin song | ash 18 | zanubrutinib (bgb-3111) in relapsed/refractory mantle cell lymphoma
-
2:53
the lung cancers song - medcomic ft. neil bobenhouse
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
10:42
understanding mantle cell lymphoma with jia ruan, md, ph.d.
-
3:51
selecting therapy for relapsed/refractory mcl
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
1:08
dr. gerson on updates in relapsed/refractory mcl
-
1:32
dr. zelenetz on zanubrutinib research in mcl
-
0:44
dr. tam on zanubrutinib approval in mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
1:29
dr. leslie on the role of zanubrutinib in mcl
-
1:26
dr. patel discusses zanubrutinib in mcl
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
4:06
identifying unmet needs in relapsed/refractory mcl
-
1:13
dr. leslie on remaining questions address in mcl
-
0:47
lori leslie, md, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
-
7:51
relapsed/refractory mantle cell lymphoma
-
4:52
therapy for relapsed or refractory mcl